Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus

被引:51
作者
Blonde, Lawrence [1 ]
机构
[1] Ochsner Med Ctr, Dept Diabet Endocrinol & Metab, Ochsner Diabet Clin Res Unit, New Orleans, LA 70121 USA
关键词
Algorithm; Hemoglobin A(1c); Treatment guidelines; Type 2 diabetes mellitus; GLYCEMIC CONTROL; AMERICAN-COLLEGE; STATEMENT; ASSOCIATION; MANAGEMENT; GLUCOSE; PREVENTION; THERAPY;
D O I
10.1016/j.amjmed.2009.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus and obesity are associated with increased cardiovascular risk. While lifestyle interventions such as medical nutrition therapy and appropriately prescribed physical activity remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. Fortunately, many of these patients are able to achieve desired glycemic targets with the use of currently available antihyperglycemic agents. Both not-for-profit disease-specific organizations and healthcare specialty societies have provided guidance about the appropriate selection of these therapies. Type 2 diabetes treatment guidelines and algorithms have been developed, taking into account a combination of evidence-based information and expert opinions, with various groups offering diverse glucose goals and approaches to hyperglycemia management. Virtually all recognize that type 2 diabetes is a multifaceted disease, necessitating an integrated yet individualized approach to patient care. (C) 2010 Published by Elsevier Inc. The American Journal of Medicine (2010) 123, S12-S18
引用
收藏
页码:S12 / S18
页数:7
相关论文
共 37 条
[1]  
*ACT NOW STUD, 2008, PIOGL PREV CONV DIAB
[2]   National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007 [J].
Alexander, G. Caleb ;
Sehgal, Niraj L. ;
Moloney, Rachael M. ;
Stafford, Randall S. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (19) :2088-2094
[3]  
*AM DIAB ASS, 2008, DIABETES CARE S1, V32, pS61
[4]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[5]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[6]  
[Anonymous], 2008, NAT DIAB FACT SHEET
[7]  
[Anonymous], 2008, Can J Diabetes, V32, pS1, DOI DOI 10.1503/CMAJ.080554
[8]  
[Anonymous], 2007, Endocrine Practice, V13, P1
[9]  
BURANT CF, 2008, MED MANAGEMENT TYPE, P33
[10]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077